Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies

Under science chief Dan Skovronsky, Eli Lilly has taken some big swings at next-gen therapies, including trying to find the next big thing in oncology. Now, after one early failure in the field, Lilly is going back to the bispecific antibody well with a new deal with a Dutch biotech.